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Abstract
 
Human mast cells (hMCs) derived in vitro from cord blood mononuclear cells exhibit stem cell
factor (SCF)-dependent comitogenic responses to T helper cell type 2 (Th2) cytokines. As cys-
teinyl leukotriene (cys-LT) biosynthesis is a characteristic of immunoglobulin (Ig)E-activated
mucosal hMCs, we speculated that Th2 cytokines might regulate eicosanoid generation by
hMCs. After passive sensitization for 5 d with IgE in the presence of SCF, anti-IgE–stimulated
 
hMCs elaborated minimal cys-LT (0.1 
 
6
 
 0.1 ng/10
 
6
 
 hMCs) and abundant prostaglandin
(PG)D
 
2 
 
(16.2 
 
6
 
 10.3 ng/10
 
6
 
 hMCs). Priming of hMCs by interleukin (IL)-4 with SCF during
passive sensitization enhanced their anti-IgE–dependent histamine exocytosis and increased
their generation of both cys-LT (by 27-fold) and PGD
 
2
 
 (by 2.5-fold). Although priming with
IL-3 or IL-5 alone for 5 d with SCF minimally enhanced anti-IgE–mediated cys-LT generation,
these cytokines induced further six- and fourfold increases, respectively, in IgE-dependent cys-
LT generation when provided with IL-4 and SCF; this occurred without changes in PGD
 
2
 
 gen-
eration or histamine exocytosis relative to hMCs primed with IL-4 alone. None of these cyto-
kines, either alone or in combination, substantially altered the levels of cytosolic phospholipase
A
 
2 
 
(cPLA
 
2
 
), 5-lipoxygenase (5-LO), or 5-LO activating protein (FLAP) protein expression by
hMCs. In contrast, IL-4 priming dramatically induced the steady-state expression of leukotriene
C
 
4
 
 synthase (LTC
 
4
 
S) mRNA within 6 h, and increased the expression of LTC
 
4
 
S protein and
functional activity in a dose- and time-dependent manner, with plateaus at 10 ng/ml and 5 d,
respectively. Priming by either IL-3 or IL-5, with or without IL-4, supported the localization of
5-LO to the nucleus of hMCs. Thus, different Th2-derived cytokines target distinct steps in the
 
5-LO/LTC
 
4
 
S biosynthetic pathway (induction of LTC
 
4
 
S expression and nuclear import of 5-LO,
respectively), each of which is necessary for a full integrated functional response to IgE-depen-
dent activation, thus modulating the effector phenotype of mature hMCs.
Key words: eicosanoids • asthma • allergy • prostaglandin D
 
2
 
 • Fc
 
e
 
RI
 
Introduction
 
Mast cells (MCs)
 
1
 
 are stem cell factor (SCF)-dependent he-
matopoietic cells that home to tissues as committed progen-
itors and then mature and differentiate into heterogeneous
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Abbreviations used in this paper:
 
 BMMC, bone marrow–derived MC;
cPLA
 
2
 
, cytosolic phospholipase A
 
2
 
;
 
 
 
cys-LT, cysteinyl leukotriene; Fc
 
e
 
RI,
high-affinity Fc receptor for IgE; FLAP, 5-LO activating protein; hMC,
human MC; 5-LO, 5-lipoxygenase; LT, leukotriene; LTC
 
4
 
S, LTC
 
4
 
 syn-
thase; MC, mast cell; PGD
 
2
 
S, PGD
 
2
 
 synthase; PGHS, prostaglandin en-
doperoxide H synthase; RP, reverse phase; SCF, stem cell factor.
 
phenotypes (1–3). When stimulated by their high-affinity
Fc receptor for IgE (Fc
 
e
 
RI), MCs generate a range of bio-
active products implicated in allergic and asthmatic inflam-
mation. Among these products are the eicosanoid metabo- 
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lites of cell membrane–derived arachidonic acid: PGD
 
2
 
 (4),
a product of the prostaglandin endoperoxide H synthase
(PGHS)/PGD
 
2
 
 synthase (PGD
 
2
 
S) pathway, and leukotriene
(LT)C
 
4
 
, a product of the 5-lipoxygenase (5-LO)/LTC
 
4
 
synthase (LTC
 
4
 
S) pathway (5). Cell activation by Fc
 
e
 
RI
initiates both pathway sequences with liberation of mem-
brane stores of arachidonic acid by a calcium-dependent
cytosolic phospholipase A
 
2
 
 (cPLA
 
2
 
; reference 6). Constitu-
tive PGHS-1 and inducible PGHS-2, integral proteins of
the perinuclear membrane and endoplasmic reticulum, pro-
vide substrate, PGH
 
2
 
, to cytosolic, glutathione-dependent
PGD
 
2
 
S (7–9). Human MCs (hMCs) release PGD
 
2
 
 during
the early bronchoconstrictor response to inhaled allergen
challenge (10). PGD
 
2
 
 may contribute to bronchoconstric-
tion in aspirin-sensitive asthma (11) and to the development
of allergic airway inflammation through its interaction with
its receptor on bronchial epithelial cells (12).
In response to cell activation, 5-LO reversibly translo-
cates from either the nucleoplasm or cytoplasm, depending
on the cell type, to the perinuclear region (13), and acts in
concert with 5-LO activating protein (FLAP [14]), an inte-
gral perinuclear protein, to convert arachidonic acid se-
quentially to the unstable intermediates 5-hydroperoxy-
eicosatetraenoic acid (5-HPETE) and then to LTA
 
4
 
 (15).
LTA
 
4
 
 either is converted by LTA
 
4
 
 hydrolase (16) to LTB
 
4
 
(as occurs in neutrophils and monocytes) or is conjugated
to reduced glutathione by LTC
 
4
 
S (17–19), an integral peri-
nuclear membrane protein with homology to FLAP that is
expressed by eosinophils, basophils, MCs, and monocytes.
LTC
 
4
 
 is released by a distinct cellular export mechanism
(20) and converted sequentially to the receptor-active cys-
teinyl LTs (cys-LTs), LTD
 
4 
 
and LTE
 
4
 
, by extracellular
 
g
 
-glutamyl transferase and dipeptidase, respectively (21,
22). LTC
 
4
 
, LTD
 
4
 
, and LTE
 
4
 
 then act at specific receptors,
including the CysLT1 receptor (23) and CysLT2 receptor
(24), to mediate a variety of cellular effects germane to
asthma, including bronchoconstriction, alterations in venu-
lar permeability, leukocyte extravasation, and mucus hy-
persecretion (25–28). The role for the cys-LT in asthma is
now substantiated by the clinical efficacy of pharmacologic
agents that interfere with the actions of 5-LO or that block
the CysLT1 receptor (29, 30).
hMCs differ in their profiles of eicosanoid biosynthesis in
response to Fc
 
e
 
RI-dependent activation after isolation
from various dispersed tissue sources. Both total cys-LT
generation (from 3.5 ng/10
 
6
 
 hMCs from skin to 45 ng/10
 
6
 
hMCs from uterus) and the cys-LT/PGD
 
2
 
 ratio (1:12 for
skin hMCs; 1:3, 1:2, and 1:1 for lung, uterine, and intesti-
nal hMCs, respectively) are marked by tissue-related differ-
ences that are both quantitative and relative (31–34). Be-
cause MCs in all tissues derive from a single lineage of
circulating committed progenitors (2, 35, 36) under the in-
fluence of constitutively expressed SCF, we postulated that
their heterogeneous profiles of eicosanoid generation
would be determined by the absence or presence of addi-
tional local factors, particularly the cytokines derived from
the Th2 lymphocytes that associate with mucosal surfaces
in allergic diseases.
 
We recently reported the derivation in vitro of hMCs
from umbilical cord blood mononuclear cells cultured in
the presence of recombinant human SCF, IL-6, and IL-10
(37). These cells were characterized by uniformly high lev-
els of c-
 
kit
 
 expression, expression of CD13 and low-level
Fc
 
e
 
RI
 
a
 
, and uniform toluidine blue metachromasia and
immunoreactivity for both tryptase and chymase. The re-
ceptors for IL-3 and IL-5 were detected on these hMCs
by flow cytometry, and the corresponding recombinant
ligands induced a comitogenic response when provided
with SCF. We now demonstrate that IL-4, in addition to
its recognized inductive effect on Fc
 
e
 
RI expression (38),
strongly and selectively upregulates the expression of
LTC
 
4
 
S mRNA, protein, and biosynthetic function. How-
ever, the inclusion of either IL-3 or IL-5 with IL-4 during
priming selectively further increases IgE-dependent cys-LT
production by hMCs, without altering PGD
 
2
 
 production,
by favoring nuclear import of 5-LO. Thus, the distinct ef-
fects of Th2 cytokines control the integrated function of
the 5-LO/LTC
 
4
 
S pathway in SCF-dependent hMCs.
 
Materials and Methods
 
Cytokines.
 
Recombinant human SCF was a generous gift
from Amgen. The cytokines IL-3, IL-4, and IL-5 (PeproTech),
IL-6 (R&D Systems), and IL-10 (Endogen) were purchased as
noted.
 
Cell Culture.
 
Cord blood was obtained from human placentas
after routine Caesarian section in accordance with established in-
stitutional guidelines. hMCs were derived by the culture of the
mononuclear cell fraction as described previously (37). In brief,
heparin-treated cord blood was sedimented with 4.5% dextran
solution to remove erythrocytes. The buffy coats were layered
onto 1.77 g/liter Ficoll-Hypaque (Amersham Pharmacia Bio-
tech), and mononuclear cell interfaces were obtained after cen-
trifugation. Residual erythrocytes were removed by hypotonic
lysis, and the remaining mononuclear cells were suspended in
RPMI 1640 (GIBCO BRL) containing 10% fetal bovine serum,
2 mM 
 
l
 
-glutamine, 0.1 mM nonessential amino acids, 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 
 
m
 
g/ml gentamycin (all
from Sigma-Aldrich), and 0.2 
 
m
 
M 2-mercaptoethanol (GIBCO
BRL). Cells were seeded at a concentration of 10
 
6
 
 cells/ml and
were cultured in the presence of 100 ng/ml SCF, 50 ng/ml IL-6,
and 10 ng/ml IL-10. The nonadherent cells were transferred ev-
ery week for up to 9 wk into culture medium containing fresh
cytokines. Cytospin preparations were examined weekly from
samples of 2 
 
3
 
 10
 
4
 
 cells using a cytocentrifuge (Shandon) and
were stained with toluidine blue to assess metachromasia. Once
cells reached maturity, defined by 
 
.
 
95% toluidine blue positivity
and positive immunostaining for both tryptase and chymase (37),
no other immunocytochemical or functional differences were
noted between 6- and 9-wk cells. Therefore, cells were used for
this study when they reached 
 
.
 
95% toluidine blue positivity
rather than a specific number of weeks in culture. No quantita-
tive or qualitative changes in cell responsiveness to cytokine
treatments were observed that were age dependent.
 
Analysis of Cys-LT and PGD
 
2
 
 Production and Histamine Release
by hMCs after Passive IgE Sensitization and Anti-IgE Activation.
 
hMCs were washed twice in medium alone and were resus-
pended in medium containing SCF (100 ng/ml) and semipurified
human myeloma IgE (10 
 
m
 
g/ml; Chemicon). Cells were incu- 
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bated with combinations of additional cytokines, including IL-3
(5 ng/ml), IL-4 (10 ng/ml), and IL-5 (5 ng/ml). The 10 ng/ml
concentration of IL-4 and the 5-d period of priming were each
chosen so as to optimize the expression and function of Fc
 
e
 
RI
(38). The concentration of IL-3 was selected based on prelimi-
nary dose–response experiments for cys-LT generation with 10
ng/ml IL-4 and SCF. The concentration-response for 1, 5, and
10 ng/ml IL-3 on IL-4–primed hMCs was 3.4, 16.0, and 25.5 ng
cys-LT/10
 
6
 
 hMCs, respectively. The dose of 5 ng/ml IL-3 was
chosen as it was also the optimal concentration for comitogenesis
(37). The dose of IL-5 was chosen for similar reasons. The hMCs
were stimulated with a rabbit anti–human IgE Ab (ICN Biomed-
icals) at a concentration of 1 
 
m
 
g/ml for 30 min at 37
 
8
 
C. Cell su-
pernatants were harvested and stored at 
 
2
 
70
 
8
 
C before assay. Cell
pellet fractions were resuspended in medium and lysed by three
cycles of rapid freezing and thawing. Histamine in the superna-
tant and cellular pellet fractions was measured by histamine
ELISA (ICN Biomedicals). Percentage of histamine release was
quantitated by the equation: histamine in supernatant/(histamine
in supernatant 
 
1
 
 histamine in pellet) 
 
3
 
 100. Cys-LT generation
in the supernatant was measured with an ELISA for LTC
 
4
 
/D
 
4
 
/E
 
4
 
(Amersham Pharmacia Biotech). For this ELISA, the cross-reac-
tivity with LTC
 
4
 
 is 100%, LTD
 
4
 
 is 100%, LTE
 
4
 
 is 70%, and LTB
 
4
 
is 0.3%. PGD
 
2
 
 generation in the supernatant was measured with
an ELISA for PGD
 
2 
 
(Cayman Chemical). For the PGD
 
2
 
 ELISA,
the cross-reactivity with TXB
 
2
 
, PGF
 
2a
 
, or PGE
 
2
 
 is 
 
,
 
0.01%. The
ratios of cys-LT to PG-D
 
2
 
 were calculated as the mean 
 
6
 
 SD of
the respective ratios determined for each condition in each indi-
vidual experiment.
For measurement of cys-LT generation by reverse phase (RP)-
HPLC, hMCs were primed and activated as above. Cell superna-
tants were collected and three volumes of cold methanol contain-
ing 400 ng/ml of PGB
 
2
 
 were added. After centrifugation in a
microcentrifuge (Eppendorf) for 5 min at maximum speed at room
temperature, the clarified methanolic extracts were removed and
applied to a 5-
 
mm 4.6 3 250 mm C18 Ultrasphere RP-HPLC
column (Beckman Coulter) equilibrated with 100% methanol/
acetonitrile/water/acetic acid (10:15:100:0.2, vol/vol, pH 6.0;
solvent A). RP-HPLC was performed with a model 126 dual
pump system and a model 167 scanning UV detector (Beckman
Instruments) with Beckman System Gold software. After injec-
tion of the sample, the column was eluted at a flow rate of 1 ml/
min with a programmed concave gradient (System Gold curve 6)
to 55% of the equilibrated solvent A and 45% methanol (solvent
B) over 2.5 min. After 5 min, solvent B was increased linearly to
75% over the next 15 min and was maintained at this level for an
additional 15 min. UV absorbance at 235 and 280 nm was re-
corded. The retention times for PGB2, LTB4, LTC4, LTD4,
LTE4, and 5-HETE were 20.7, 24.0, 21.6, 23.6, 26.0, and 30.2
min, respectively. The resolved products were quantitated by cal-
culating the ratio of the peak areas to the area of the internal stan-
dard PGB2 (18). When synthetic LTC4 or mixtures of synthetic
LTD4 and LTE4 (Cayman Chemical) were analyzed using both
RP-HPLC and ELISA, the total product measured by ELISA was
consistently greater than that measured by RP-HPLC by a maxi-
mum of 20%.
SDS-PAGE Immunoblot Analysis. Whole cell extracts were
prepared by washing cells in cold PBS and then boiling them in
Tris-glycine/bromophenol blue lysis buffer (Novex) containing
0.5% 2-ME at a concentration of 107 cells/ml of lysis buffer for
10 min. After SDS-PAGE with 14% Tris-glycine gels (Novex),
the proteins from 105 cells/lane were electrophoretically trans-
ferred to 0.45-mm nitrocellulose membranes (Bio-Rad Laborato-
ries). Nonspecific binding was blocked with 3% wt/vol nonfat
milk (Bio-Rad Laboratories) in Tris-buffered saline (TBS) con-
taining 0.1% wt/vol Tween 20 and 0.5% normal goat serum
(Caltag). Detection of LTC4S with primary Abs used a 1:500 di-
lution of affinity-purified rabbit polyclonal antipeptide Ab (0.192
mg/ml) directed against the carboxyl-terminal 15 amino acids
of human LTC4S (protein sequence RAALLGRLRTLLWPA).
This Ab does not cross-react with human FLAP, human m-glu-
tathione-S-transferase II, or mouse LTC4S on immunoblot, and
recognizes only human LTC4S in multiple tissue and cellular ly-
sates. Additional primary Abs used in this study included rabbit
polyclonal anti–5-LO Ab (J. Evans, Merck-Frosst Centre, Que-
bec, Canada [15]) at 1:5,000 dilution, rabbit polyclonal anti-
FLAP Ab (15) at 1:5,000 dilution, and rabbit polyclonal anti-
cPLA2 Ab (Santa Cruz Biotechnology, Inc.) at 1:1,000 dilution.
After the membranes were washed, the proteins were detected
with a secondary goat anti–rabbit IgG labeled with horseradish
peroxidase (Bio-Rad Laboratories) followed by enhanced chemi-
luminescence (ECL; Amersham Pharmacia Biotech). SDS-PAGE
immunoblots were quantitated using a ChemiImager 4400 densi-
tometer with AlphaEase v5.0 software (Alpha Innotech Corpora-
tion).
RNA Blot Analysis. Total RNA was extracted from 107 cells
with Tri-reagent (Molecular Research Center [39]). After extrac-
tion with chloroform followed by overnight precipitation in iso-
propanol, total RNA was washed with 70% ethanol and purity
was assessed by spectrophotometry (DU 640; Beckman Coulter).
Then, 14 mg of total RNA was loaded into a 1.2% agarose gel
with 13 MOPS (3-[N-morpholino] propan-sulfonic acid) buffer
containing 20% formaldehyde. After electrophoresis, RNA was
transferred to nylon membranes (Micron Separations) by capillary
action overnight. RNA was fixed to the membrane by baking at
808C for 1 h. The blot was prehybridized in 53 standard sodium
phosphate with EDTA (SSPE; GIBCO BRL) containing 23
Denhardt’s solution, 0.25% SDS, 50% formamide, and 100 mg/
ml denatured salmon sperm DNA (GIBCO BRL) overnight at
438C. The blot was then probed with human LTC4S cDNA (18)
or human 18S ribosomal RNA (CLONTECH Laboratories,
Inc.) that had been labeled with [32P]dCTP incorporated by ran-
dom priming with RediPrime II (Amersham Pharmacia Biotech).
Blots were washed at high stringency with 0.23 SSPE at 558C,
and hybridization signals were detected by autoradiography with
Kodak XAR film (Eastman Kodak Co.).
Analysis of LTC4S Activity in Lysed Cells. LTC4S activity was
determined as described (18, 39). 2 3 105 hMCs were washed
into 250 ml of 50 mmol/liter of Hepes, pH 7.6, with 10 mmol/
liter MgCl2. The cells were sonicated on ice with a Branson son-
icator three times for 5 s each. Reduced glutathione and LTA4
methyl ester were added to the cell lysates at room temperature at
final concentrations of 10 mmol/liter and 20 mmol/liter, respec-
tively. After 10 min, the reaction was terminated by adding 2
volumes of cold methanol containing 400 ng/ml of PGB2. After
centrifugation in a microcentrifuge (Eppendorf) for 5 min at
maximum speed, the supernatants were removed and applied to a
5-mm 4.6 3 250 mm C18 Ultrasphere RP-HPLC column
(Beckman Coulter) equilibrated with 100% methanol/acetoni-
trile/water/acetic acid (10:15:100:0.2, vol/vol, pH 6.0; solvent
A). After injection of the sample, the column was eluted at 1 ml/
min with a programmed concave gradient (System Gold curve 6)
to 30% of the equilibrated solvent A and 70% methanol (solvent
B) over 0.2 min. After 2.8 min, solvent B was increased linearly
to 90% over 2 min and was maintained at this level for an addi-
tional 10 min. UV absorbance at 280 nm and the UV spectra126 IL-4 Regulates LTC4 Synthase
were recorded. The retention times for PGB2 and LTC4 methyl
ester were 8.5 and 10.1 min, respectively. LTC4 methyl ester was
quantitated by calculating the ratio of the peak area to the area of
the internal standard PGB2.
Immunofluorescence and Immunocytochemistry. hMCs were fixed
in suspension with 2% paraformaldehyde in PBS for 10 min at
48C, washed once in HBSS without calcium or magnesium con-
taining 0.1% BSA (HBA), permeabilized with 100% methanol for
20 min at 2208C, and spun for 5 min at 500 rpm in a cytocentri-
fuge onto glass coverslips. The slides were then blocked in HBA
containing 5% normal horse serum (Jackson ImmunoResearch
Laboratories) for 1 h. Primary Abs rabbit polyclonal anti–5-LO
Ab (J. Evans, Merck-Frosst Centre [15]) or normal rabbit IgG
(Chemicon) were added at a 1:800 dilution in HBA, and the cells
were incubated for 1 h at room temperature. The cells were then
washed in HBA and treated for 1 h at room temperature with the
nuclear dye bis-benzimide (Hoechst no. 33258; Sigma-Aldrich)
at a 1:1,000 dilution and/or goat anti–rabbit IgG conjugated to
FITC (Jackson ImmunoResearch Laboratories) at a 1:100 dilu-
tion. After washing in HBA, cells were mounted in a 33% glyc-
erol solution in PBS containing 15% w/v vinol 205 (Air Products
and Chemicals) and 0.1% sodium azide. Cells were visualized
with 403 or 1003 oil objective lenses with a FXA microscope
(Nikon). At least 100 cells per cover slip were counted in each
experiment. The presence or absence of nuclear staining was de-
termined by superimposition of the FITC-stained images with
the Hoechst-stained images of the same cells. Each cover slip was
scored for nuclear staining of 5-LO by two independent investi-
gators blinded to the experimental conditions. The results re-
ported are the average of the percentage of positive cells reported
by the two investigators for each experiment.
For immunocytochemistry, slides with 2 3 104 hMCs were
prepared by cytocentrifugation, air dried, and fixed in Carnoy’s
fluid (60% ethanol, 30% chloroform, and 10% glacial acetic acid)
for 10 min at room temperature. After being washed with PBS
three to four times, the slides were blocked with 2% chicken egg
albumin (Sigma-Aldrich) for 30 min at room temperature, and
were incubated with an appropriate dilution of antitryptase
(Chemicon) or with an equivalent dilution of the corresponding
isotype-matched negative control (BD PharMingen). After appli-
cation of the appropriate secondary Ab, alkaline phosphatase was
used as a chromogenic reporter (37).
Statistical Analysis. Unless otherwise indicated, the results are
reported as the mean 6 SEM from at least three independent ex-
periments with the cells from different donors. As consistent
trends for cytokine effects on cys-LT generation were observed
despite wide variability among subjects in absolute quantities pro-
duced, the data for eicosanoid generation were calculated both as
absolute quantities and as the mean ratio of cys-LT/PGD2 for
each experiment. Statistical differences in immunostaining and
eicosanoid generation were determined with the independent
group Student’s t test.
Results
Effect of Th2-type Cytokines on Cys-LT and PGD2 Genera-
tion by Anti-IgE–activated hMCs. hMCs developed from
human umbilical cord blood mononuclear cells cultured in
the presence of SCF, IL-6, and IL-10 (37) were washed
and maintained with SCF (100 ng/ml) alone or with SCF
plus IL-4 (10 ng/ml) for 5 d of passive sensitization with
human IgE. When activated by the addition of anti-IgE,
hMCs primed by IL-4 released fivefold more of their secre-
tory granule–associated histamine than hMCs stimulated af-
ter maintenance with SCF alone (P 5 0.0006, n 5 4; Fig.
1), compatible with previous reports (38, 40). hMCs
treated with SCF alone during passive sensitization gener-
ated only 0.1 6 0.1 ng cys-LT/106 cells, whereas those
primed with IL-4 in the presence of SCF responded to
IgE-dependent activation with a 27-fold increase in cys-LT
production (2.7 6 1.0 ng cys-LT/106 cells, P 5 0.03, n 5
4; Fig. 1). PGD2 generation by hMCs in SCF alone in-
creased from a substantial amount (16.2 6 10.3 ng/106
hMCs) to 39.1 6 18.5 ng/106 hMCs (P 5 0.17, n 5 4;
Fig. 1) when the cells were primed with IL-4. IL-4 priming
produced an increment in both cys-LT and PGD2 produc-
tion in every experiment.
The modest cys-LT generation even after IL-4–induced
priming for IgE-dependent activation prompted a search
for additional priming factors, with attention to the Th2
cytokines that had previously shown maximal comitogenic
activities for hMCs, IL-3, and IL-5. Priming with IL-3
alone produced a small increment in IgE-dependent cys-LT
Figure 1. Effect of IL-4 priming of hMCs on IgE-mediated histamine
release and eicosanoid generation as measured by ELISA. hMCs were
maintained in SCF and IgE for 5 d with and without 10 ng/ml of IL-4.
Results depict percent histamine release, cys-LT generation, and PGD2
production after 5 d of priming and passive sensitization followed by acti-
vation with anti-IgE (black bars) or treatment with buffer alone (hatched
bars). Results are the mean 6 SEM of four experiments and the IL-4 ef-
fect was significant for histamine (P 5 0.0006) and cys-LT (P 5 0.03).
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generation above cells maintained in SCF alone that was
evident by 24 h and maximal by 3 d (2.7 6 2.0 ng vs. 0.9 6
1.8 ng, n 5 3). Priming with IL-5 was comparable (n 5 1).
When added with SCF and IL-4 for 5 d of priming, nei-
ther IL-3 (5 ng/ml) nor IL-5 (5 ng/ml) increased the exo-
cytosis of histamine by passively sensitized hMCs chal-
lenged with anti-IgE (55 6 9% and 53 6 9% release with
the added priming of IL-3 and IL-5, respectively, vs. 73 6
8% release with IL-4 priming alone, n = 4; Fig. 2). In con-
trast, in each of these experiments, the inclusion of IL-3
during priming with IL-4 increased IgE-dependent cys-LT
generation (from 5.7 6 3.1 to 33.0 6 13.1 ng/106 hMCs,
P 5 0.05, n 5 5). The effect of IL-5 priming was similar
and present in every experiment (22.7 6 16 ng/106 hMCs,
P 5 0.17, n 5 3; Fig. 2). Priming by IL-3 plus IL-4 also
modestly increased PGD2 generation relative to priming
with IL-4 alone (from 27.2 6 5.4 to 40.3 6 12.3 ng/106
hMCs, n 5 4), whereas IL-5 did not add to the effect of IL-4
priming alone for PGD2 generation (28.3 6 2.0 ng/106
hMCs, n 5 3; Fig. 2). Because the effects of IL-3 and IL-5
were each relatively selective for cys-LT generation, their
addition significantly altered the ratio of cys-LT to PGD2
generated (from 1:14.6 for hMCs primed with IL-4 to 1:2.9
for hMCs primed with IL-3 plus IL-4 [P 5 0.05] and 1:3.7
for hMCs primed with IL-5 plus IL-4 [P 5 0.04]).
The effects of each cytokine on integrated cellular 5-LO
function can be quantitatively assessed only by RP-HPLC
analysis, permitting the simultaneous measurement of cys-
LT, LTB4, and the proximal metabolites 5-HETE and
6-trans-LTB4 (derived from nonenzymatic breakdown of
5-HPETE and LTA4, respectively). With this analysis,
hMCs maintained with SCF alone generated 0.1 6 0.2
pmoles cys-LT/106 hMCs with IgE-dependent activation,
whereas hMCs primed with IL-3 in the absence of IL-4
produced 2.7 6 1.3 pmoles cys-LT/106 hMCs (n 5 3 for
both conditions). Comparable quantities were produced by
IL-5–primed hMCs. hMCs primed by IL-4 with SCF gen-
erated 5.0 6 2.4 pmoles cys-LT/106 hMC (n 5 5) after ac-
tivation, which was increased threefold by the inclusion of
IL-3 (14.8 6 4.2 pmoles/106 hMCs, P 5 0.05, n 5 4), and
to a lesser extent by the inclusion of IL-5 (8.6 6 2.9 ng/106
hMCs, P 5 0.19, n 5 3). No 5-HETE or 6-trans LTB4
was detected under any experimental conditions. Peaks
corresponding to LTC4, LTD4, and LTE4 were detected,
with most of the product being converted to LTE4.
Effect of Th2 Cytokines on LTC4S Expression and Func-
tion. Compared with maintenance in SCF alone, priming
by IL-4 (10 ng/ml) for 5 d resulted in a marked increase in
LTC4S protein, with a slight increase in cPLA2 and no ap-
parent change in either FLAP or 5-LO (Fig. 3 a). As quan-
titated by densitometry, the mean increase in LTC4S pro-
tein signal after IL-4 treatment was fivefold (Fig. 3 b; n 5
11, P 5 0.0005). IL-13 (10 ng/ml) did not affect the ex-
pression of LTC4S or any of the other pathway proteins, as
shown for LTC4S (Fig. 4 a). With the concentration of
SCF held constant at 100 ng/ml, treatment of hMCs for 5 d
with increasing concentrations of IL-4 induced a dose-depen-
dent increase in immunodetectable LTC4S protein in every
Figure 2. Effect of IL-3 or IL-5 treatment during IL-4 priming of
hMCs for IgE-mediated release of histamine and generation of cys-LTs
and PGD2, as measured by ELISA. hMCs were activated with anti-IgE
(black bars) or buffer (hatched bars) after 5 d of passive sensitization and
priming with IL-4 in the presence of SCF with or without the addition of
IL-3 or IL-5. Results are mean 6 SEM for five (for SCF plus IL-4 and
SCF plus IL-4 plus IL-3) or three (SCF plus IL-4 plus IL-5) experiments.
Ctl., control.
Figure 3. Effect of IL-4 priming on 5-LO/LTC4S pathway protein ex-
pression by hMCs. (a) SDS-PAGE immunoblot was performed with ly-
sates from hMCs (105/lane), treated for 5 d with SCF with or without IL-
4, with polyclonal Abs specific for cPLA2, 5-LO, FLAP, and LTC4S, as
specified in Materials and Methods. The displayed blot is a single experi-
ment representative of three experiments. (b) Quantitative densitometry
revealed a fivefold increase in LTC4S signal after IL-4 treatment for 5 d
(n 5 11, P 5 0.0005).128 IL-4 Regulates LTC4 Synthase
experiment (n 5 3), apparent at the lowest concentration
tested (0.1 ng/ml), and maximal at 10 ng/ml (Fig. 4 a). The
effect of 10 ng/ml IL-4 on LTC4S protein was apparent by
1 d and maximal at 5 d (Fig. 4 b). LTC4S activity, as mea-
sured by the conversion of LTA4 methyl ester to LTC4
methyl ester, remained unchanged in lysates of hMCs treated
with SCF alone for 1 and 5 d as compared with hMCs har-
vested from the original developmental triad of SCF, IL-6,
and IL-10. In contrast, lysates of IL-4–primed hMCs re-
vealed a sevenfold increase in LTC4S activity over this time
frame (138.5 pmol to 980.5 pmol LTC4/106 hMCs, n 5 4,
P 5 0.02; Fig. 5). Compared with maintenance in SCF
alone, the addition of IL-4 (10 ng/ml) enhanced steady-
state levels of LTC4S mRNA expression by 6 h, with a pla-
teau at 24 h that continued unchanged for 5 d (n 5 2, as
shown for a representative experiment; Fig. 6).
Effect of IL-3 and IL-5 on the Cellular Localization of
5-LO. Compared with hMCs primed with SCF alone,
neither IL-3 nor IL-5 priming altered the immunodetect-
able quantities of 5-LO or FLAP, and they modestly in-
creased the baseline expression of cPLA2. IL-5, but not IL-3,
also slightly increased immunodetectable LTC4S protein
(Fig. 7). When added in combination with IL-4 in the
presence of SCF, neither IL-3 nor IL-5 produced further
increases in LTC4S protein or altered the quantities of
5-LO or FLAP proteins, and each induced slight increases
in the expression of cPLA2 above that induced by IL-4
alone (n 5 3, data not shown).
hMCs maintained for 5 d in SCF alone displayed weak
5-LO immunoreactivity predominantly in a diffuse, cyto-
plasmic distribution (as shown for one experiment; Fig. 8
d). Under these conditions, 11 6 2% of the hMCs exhib-
ited some staining of the nucleus after 5 d, which was en-
hanced only slightly by the addition of IL-4 (19 6 6%, P 5
Figure 4. Dose dependence and kinetics for the IL-4–mediated upreg-
ulation of LTC4S protein expression. (a) Dose-dependent effects at 5 d of
IL-4, from 0.1 to 50 ng/ml, on LTC4S protein with a constant concentra-
tion of SCF (100 ng/ml), as demonstrated by SDS-PAGE immunoblot.
Single lanes containing lysates from 105 hMCs treated for 5 d with SCF
alone, and with SCF plus IL-13 (10 ng/ml), are included. (b) Kinetic ef-
fects of IL-4 (10 ng/ml) on LTC4S protein in hMCs incubated for 0 to 5 d
with SCF (100 ng/ml) to maintain viability. The displayed blots are repre-
sentative of three experiments each.
Figure 5. IL-4–mediated upregulation of LTC4S biosynthetic activity.
LTA4 methyl ester and reduced glutathione were provided as substrates
to the sonicated lysates from 2 3 105 hMCs for each condition. Sonicates
were prepared from hMCs harvested from their original medium con-
taining SCF, IL-6, and IL-10 at the start of the experiment (day 0), and
again after these hMCs were treated with SCF alone (100 ng/ml) or with
SCF and IL-4 (10 ng/ml) for the indicated times. Products were resolved
by RP-HPLC and quantitated based on the internal standard PGB2 as in-
dicated in Materials and Methods. Results are mean 6 SEM for four ex-
periments.
Figure 6. IL-4–mediated upregulation of steady-state LTC4S mRNA.
(a) RNA blot analysis depicting hybridization signals for LTC4S mRNA
in samples of total RNA (14 mg/lane) extracted from hMCs that were
harvested at the indicated times after being transferred to fresh SCF-con-
taining medium with (1) or without IL-4. (b) Ribosomal 18S RNA sig-
nal in the corresponding lanes. Results are representative of two experi-
ments performed.
Figure 7. Effect of IL-3 or IL-5 priming on 5-LO/LTC4S pathway
protein expression by hMCs. SDS-PAGE immunoblot was performed
with lysates from hMCs (105/lane), treated for 5 d with SCF (100 ng/ml)
with or without IL-3 or IL-5 (5 ng/ml each), using polyclonal Abs spe-
cific for cPLA2, 5-LO, FLAP, and LTC4S as specified in Materials and
Methods. The LTC4S signal from hMCs primed for 5 d with IL-4 is in-
cluded for comparison. The displayed blot is a single experiment repre-
sentative of three experiments.129 Hsieh et al.
0.12). When compared with maintenance in SCF alone
or with SCF plus IL-4, treatment with either IL-3 or with
IL-5 increased the proportion of hMCs exhibiting nuclear
staining for 5-LO by as early as 3 d. The differences were
significant by 5 d (46 6 12% with nuclear staining for
hMCs maintained with IL-3 and IL-4 plus SCF, P 5 0.05;
and 38 6 7% for hMCs maintained with IL-5 and IL-4
plus SCF, P 5 0.03). IL-3 and IL-5 each also increased the
intensity of the nuclear stain (n 5 3, as shown for a repre-
sentative experiment; Fig. 8, h and j, respectively). The ef-
Figure 8. Effects of IL-3 and IL-5 on immunolocalization of 5-LO in hMCs. hMCs were maintained for 5 d in SCF alone (a–d), with 10 ng/ml of IL-4
(e and f), with IL-4 plus 5 ng/ml of IL-3 (g and h), or IL-4 plus 5 ng/ml of IL-5 (i and j). Images on the left are photographed through a 403 objective,
whereas those on the right are photographed at 1003 for nuclear detail. Identical fields of hMCs are photographed under blue fluorescence (a, c, e, g,
and i) to show location of nuclei as identified by Hoechst staining, and under green fluorescence (FITC) to demonstrate localization of 5-LO immunore-
activity in the same cells (d, f, h, and j). FITC staining with a preimmune rabbit IgG (b) is included as a specificity control. The images are taken from a
single experiment representative of three performed, for which the mean data are presented in the text.130 IL-4 Regulates LTC4 Synthase
fects of IL-3 and IL-5 on 5-LO localization were similar in
experiments where IL-4 was omitted (55 6 19% and 34 6
14% positive, respectively, mean 6 1/2 range for two of
the experiments presented above). Immunofluorescence
with control rabbit IgG gave almost no background stain-
ing (Fig. 8 b).
Discussion
The effector molecules implicated in the pathogenesis of
bronchial asthma include the lipid mediators provided by
hMCs and eosinophils (10, 25, 41) and the cytokines pro-
vided by Th2 cells. hMCs derived from cord blood with
the triad of SCF, IL-6, and IL-10 express the receptors for
IL-3 and IL-5 (37), and both of these Th2 cytokines medi-
ate comitogenic responses from hMCs in the presence of
SCF. hMCs respond to a third Th2 cytokine, IL-4, with
augmented FceRI expression and IgE-dependent activa-
tion responses (38, 40). IL-3 and IL-5 promote the devel-
opment in vitro of cord blood–derived eosinophils that ex-
press all proteins of the 5-LO/LTC4S pathway (39) and
that generate cys-LT after stimulation with calcium iono-
phore. Unlike eosinophils, which do not produce PGD2,
hMCs generate both PGD2 and cys-LT, the latter of which
exhibits wide variability among hMCs obtained from vari-
ous dispersed tissues (31–34). Thus, both arms of the
eicosanoid-generating pathways of hMCs were assessed for
the regulatory effects of Th2 cytokines. We found that
although cord blood–derived hMCs maintained in SCF
alone generated abundant PGD2 after IgE-dependent acti-
vation even without Th2 cytokine priming, their optimal
cys-LT generation required the coordinate actions of IL-4
with either IL-3 or IL-5, which mediate separate and dis-
tinct steps in priming the 5-LO/LTC4S pathway for an in-
tegrated functional response.
For all priming conditions, SCF was included to ensure
maximal hMC viability. A marked (27-fold) increase in
cys-LT generation (Fig. 1) was observed when hMCs were
primed with IL-4 before activation. This was attributable
to two events. First, IL-4 priming augmented IgE-depen-
dent exocytosis of histamine by fourfold (Fig. 1), an effect
attributable to the previously recognized upregulation of
FceRI by IL-4 (38, 40). Second, and unexpectedly, IL-4
induced a dramatic upregulation of LTC4S transcript (Fig.
6), protein (Figs. 3 and 4), and function (Fig. 5). This
marked induction by IL-4 was relatively selective for
LTC4S among the 5-LO/LTC4S pathway proteins (Fig. 3).
IL-13 at a concentration of 10 ng/ml did not upregulate
LTC4S protein (Fig. 4). In previous studies, IL-13 failed to
augment FceRI expression by cord blood hMCs (38), and
was not comitogenic with SCF (37). The fact that hMCs
respond markedly to IL-4 but not to IL-13 suggests that
they may express the ag IL-4 receptor heterodimer associ-
ated with T cells rather than the IL-4 receptor type II con-
sisting of the IL-4Ra and IL-13Ra1 subunits found mainly
in B cells and nonhematopoietic cells (42). The parallel IL-
4–mediated regulation of both FceRI and LTC4S, the bio-
synthetic enzyme responsible for cys-LT leukotriene gen-
eration, would fit the pivotal role of Th2 cells in bronchial
asthma and supports a direct regulatory role for lympho-
cytes in the control of hMC function.
Although IL-4 priming of hMCs did induce their IgE-
dependent cys-LT generation, the modest quantities of cys-
LTs produced, relative to the abundant generation of
PGD2, led us to explore possible additional priming events.
IL-3 and IL-5 were maximally comitogenic for hMCs from
among a panel of Th2 cytokines tested in our earlier studies
(37). When added without IL-4, IL-3 or IL-5 provided an
increment in cys-LT production comparable to IL-4 alone
by hMCs after IgE-dependent activation. In contrast, the
inclusion of IL-3 or IL-5 with IL-4 resulted in a six- or
fourfold increase, respectively, in IgE-dependent cys-LT
production, without a dramatic change in either PGD2
generation or percentage of histamine release (Fig. 2).
These findings indicate a selective action of IL-3 and IL-5
on the function of the 5-LO/LTC4S pathway. The prim-
ing effect of IL-3 and IL-5 involved the redistribution of
5-LO to the hMC nucleus (Fig. 8), which did not require
the presence of IL-4, and was temporally concomitant with
a functional effect evident by incremental cys-LT genera-
tion. Our studies thus reveal two Th2-dependent require-
ments for the integrated function of the 5-LO/LTC4S
pathway in cultured hMCs. IL-4 is necessary to upregulate
FceRI expression and to induce LTC4S expression,
whereas IL-3 or IL-5 positions 5-LO for its subsequent uti-
lization of arachidonic acid in the presence of FLAP at the
nuclear envelope after IgE-dependent activation. Neither
event alone is sufficient for the full expression of cys-LT
production, but each acts synergistically with the other to
promote a marked phenotypic change in hMCs.
The human LTC4S gene is localized to chromosome
5q35 (43), close to a locus identified by linkage analysis to
have gene candidates for asthma and atopy (44, 45). Regu-
latory cis-acting elements and transcription factors for the
proximal core promoter of the human LTC4S gene in
THP-1 cells include a non–cell-specific basal promoter and
a cell-specific upstream enhancer region (46). The effect of
IL-4 on LTC4S expression may reflect increased LTC4S
transcription or could result from increased mRNA stabil-
ity. A monocyte-like cell line, THP-1, responds to TGF-b
with increased steady-state LTC4S mRNA expression by a
transcription-dependent mechanism, without an effect on
LTC4S transcript stability (47). IL-4 could also influence
trafficking of nascent LTC4S protein to the perinuclear
membrane and endoplasmic reticulum. The latter may ac-
count for the lag between plateau mRNA expression (24 h)
and protein expression (5 d) in this study. Maximal expres-
sion of LTC4S steady-state mRNA also preceded the pla-
teau for expression of immunodetectable LTC4S protein by
several days in culture-derived eosinophils (39). The find-
ings in earlier studies that IL-3– and IL-5–driven eosinophil
differentiation from cord blood progenitors in vitro was ac-
companied by marked induction of LTC4 transcript and
protein (39), and the findings in this study that maximal ex-
pression of LTC4S by hMCs requires induction by IL-4, in-
dicate that cell-specific regulation of LTC4S expression dif-131 Hsieh et al.
fers among effector cell types. Such cell-specific regulation
may explain the profound upregulation of LTC4S in eo-
sinophils, but not hMCs, in lung tissue biopsy specimens
from patients with aspirin-sensitive asthma (48).
Although mouse bone marrow–derived MCs (BMMCs)
can develop in vitro in response either to SCF with IL-6
and IL-10 (36) or to IL-3 alone (49), normal MC develop-
ment in mice in vivo is SCF-dependent (50–52). IL-3–
derived BMMCs express 5-LO in their nucleus at baseline
(13) and preferentially generate cys-LTs over PGD2 when
activated via FceRI. However, priming of these IL-3–
driven BMMCs in vitro with SCF preferentially increases
their capacity for PGD2 generation by augmenting their
expression of cPLA2, PGHS-1, and PGD2S (53). The ap-
parently innate capacity for all tissue subpopulations of
hMCs to generate PGD2 may therefore reflect their SCF
dependency in vivo. Our data confirm that SCF alone is
sufficient to support a PGD2-producing hMC population
in vitro that is similar in eicosanoid product profile to
hMCs from dispersed human skin (32). The previously re-
ported capacity for IL-3 to upregulate cys-LT generation
by SCF-driven mouse BMMCs (54) was associated with
progressive increases in 5-LO and FLAP expression over 2
wk, followed at 4 to 5 wk by augmented LTC4S expression
concomitantly with a 12-fold increase in total BMMC
numbers. In contrast, hMCs in our study did not increase
in number during 5 d of cytokine priming, indicating that
their cytokine-induced cys-LT biosynthetic capacity repre-
sented a phenotypic change, with a transition from a
PGD2-dominant profile of arachidonic acid metabolism to
a nearly equivalent PGD2/cys-LT profile reminiscent of
dispersed lung or intestinal hMCs (33, 34).
Under resting conditions 5-LO localizes to the cytosol of
neutrophils, but is in the nuclear euchromatin of alveolar
macrophages, RBL cells, and mouse BMMCs cultured in
WEHI medium (which contains murine IL-3 [55–58]). In
each of these cells, 5-LO translocates to the nuclear enve-
lope during activation-dependent LT generation. Nuclear
import of 5-LO from the cytoplasm of neutrophils is asso-
ciated with priming for subsequent enhanced calcium ion-
ophore A23187-induced LT generation (58), possibly re-
flecting enhanced proximity to the other enzymes involved
in LT biosynthesis. In our study, only a small minority of
hMCs incubated with SCF alone or SCF plus IL-4 for 5 d
showed nuclear staining for 5-LO. Priming with IL-3 or
IL-5 increased the proportion of hMCs exhibiting nuclear
staining for 5-LO at 5 d (as shown in a representative ex-
periment; Fig. 8), an effect which did not require the pres-
ence of IL-4. Our study thus suggests that the priming ef-
fects of IL-3 and IL-5 for cys-LT production by hMCs
includes the nuclear import of 5-LO, and may involve
other mechanisms such as a slight upregulation of cPLA2
(Fig. 7). Translocation of 5-LO from the cytosol to the nu-
cleus has been proposed to explain IL-5–mediated priming
of ionophore-stimulated LTC4 production by human pe-
ripheral blood eosinophils (59).
An array of Th2 cytokines, including both IL-5 and IL-
4, is strongly expressed through the influx of Th2 cells in
bronchial biopsy specimens from patients with asthma rela-
tive to individuals without asthma (60). IL-3 protein is lo-
calized to the bronchial epithelium in individuals with and
without asthma (61). The increased numbers of hMCs in
the bronchial mucosa of patients with newly diagnosed
asthma (62) may reflect the comitogenic actions of Th2 cy-
tokines on this SCF-dependent lineage. The fact that endo-
bronchial allergen challenge elicits markedly increased
quantities of cys-LTs in the bronchoalveolar lavage fluids of
patients with asthma relative to control individuals with al-
lergic rhinitis alone (41) may reflect disease-related pheno-
typic modifications of local hMCs induced by these same
cytokines. Our study demonstrates that Th2 cytokines alter
the profile of eicosanoids generated by mature hMCs, and it
is the first to suggest a mechanistic basis for this phenotypic
change. Furthermore, our findings suggest that hMCs,
which depend on SCF for their normal development and
survival, have a constitutive arachidonic acid phenotype
that is characterized by PGD2 generation predominating
markedly over cys-LT generation. This arachidonic acid
profile of PGD2 .. cys-LT is substantially modified, with
a profound increment in cys-LTs, by priming the hMCs
with IL-4 to induce LTC4S and with IL-3 or IL-5 to main-
tain 5-LO at the nucleus before FceRI-mediated activation.
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